Dr. Vlad Coric brings a wealth of clinical development expertise to the Pyramid Biosciences Board, having shepherded numerous drugs from first-in-human studies all the way through successful Phase 3 pivotal trials to FDA approvals. Dr. Coric currently serves as the CEO of Biohaven Pharmaceuticals (NYSE: BHVN), a multibillion dollar biotech company that he took public in 2017 which recently received its first FDA approval in 2020 for NurtecTM ODT (rimegepant).
Prior to joining Biohaven, Dr. Coric served as the head of the neuro-oncology clinical division at Bristol-Myers Squibb where he designed and led the first global registration trial using checkpoint inhibitors in glioblastoma. During his time at BMS, Dr. Coric was involved with multiple drug development programs across several therapeutic areas, including marketed drugs such as Abilify (aripiprazole; partial dopamine agonist), Opdivo (nivolumab; anti-PD1), Yervoy (Ipilimumab; anti-CTLA-4), Daklinza (daclatasvir; NS5A inhibitor) and Sunvepra (asunaprevir; NS3 inhibitor). Dr. Coric also serves as an Associate Clinical Professor at the Yale School of Medicine and is a graduate of Wake Forest University School of Medicine.